I found it! Sunday, IDEC will present clincal data on CE9.1 for severe asthma at the ATS/ALA. I will try to check in out if I can. Here is the abstract from the program...
[A74] A Double-Blind, Placebo-Controlled Trial of an Anti-CD4 Monoclonal Antibody, SB210396, in Chronic Severe Asthma
O. M. Kon, C. H. Compton, A. B. Kay, N. C. Barnes, London, England
Sunday, 5/18/97, , Yerba Buena Salon 9 (Lower B-2 Level), MARRIOTT HOTEL
There is accumulating evidence of a central role for the CD4+ T lymphocyte in asthmatic inflammation. We have investigated the effect of a single intravenous infusion of SB210396 (IDEC CE9.1), a Primatized^{(r)} anti-CD4 monoclonal antibody (mAb) in severe oral corticosteroid-dependent asthmatics. Six patients received 0.5mg/kg, 5 patients 1.5mg/kg, 5 patients 3.0mg/kg and 6 patients placebo. Patients receiving 0.5 and 1.5mg/kg showed no change. At 3.0mg/kg there was a significant increase in area under the curve from day 0-28 for morning and evening peak expiratory flow rate (PEFR) (p=0.017 and p=0.004). Two patients had worsening of their eczema and one patient had a maculo-papular rash. There were no serious adverse events related to treatment.
(See original for figure)
These results demonstrate that SB210396, a specific anti-CD4 mAb, is active in severe corticosteroid-dependent asthmatics and provide further evidence for an important role of CD4+ T lymphocytes in the pathogenesis of chronic asthma.
This abstract is funded by: SmithKline Beecham Pharmaceuticals
[**] Mini-Symposium
Abstract Page: A203
Session: 1:30 pm-4:15 pm, NEW DEVELOPMENTS IN ASTHMA THERAPY |
